PPIDT00247
Drug Information
| Name | Teduglutide |
|---|---|
| Sequence | HGDGSFSDEMNTILDNLAARDFINWLIQTKITD |
| DrugBank_ID | DB08900 |
| Type | biotech |
| Indication | Teduglutide is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support.[L39870] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, lyophilized, for solution | Subcutaneous |
5 mg/0.5mL
|
| Injection, powder, lyophilized, for solution; kit | Subcutaneous; Topical |
|
| Injection, powder, for solution | Parenteral; Subcutaneous |
1.25 MG
|
| Injection, powder, for solution | Parenteral; Subcutaneous |
5 MG
|
| Injection, powder, for solution | Subcutaneous |
1.25 mg
|
| Injection, powder, for solution | Subcutaneous |
5 mg
|
| Kit; powder, for solution | Subcutaneous |
5 mg / vial
|
| Injection, powder, for solution | Subcutaneous |
500000 mg
|